Meet us at ISPOR Europe 2018, in Barcelona (10-14 November)!
That time of the year has come again, when the

Ingress-health ISPOR contributions
 
On November 10-14, the vibrant city of Barcelona, Spain, will host the annual ISPOR Europe Conference.

In its latest publication, using the example of COPD (paper available here), a team of Ingress-health real-world evidence experts explored whether

Ingress-health has conducted a multi-center patient preference study addressing atrial fibrillation patients’ preferences for their oral anticoagulation treatment. The results

The Spanish office will be lead by Pablo Rebollo. Pablo has over 20 years of experience in Spanish market access

We are happy to share with you our latest publication on time-to-event outcomes in patients with nonmetastatic castration-resistant prostate cancer

Ingress Health is a young, dynamic health economics and outcomes research consultancy.
Our mission is to find the unexplored value

The poster “Real-world treatment persistence and associated costs with biologic therapy in patients with Inflammatory Bowel Disease (IBD): Results of

Interested in the cost-effectiveness of cetuximab vs bevacizumab in the 1L treatment of RAS wild-type metastatic colorectal cancer in Germany? 

Sabrina Mueller from our German office will present three research posters at the ASH conference. All three deal with oral